TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30678635

Group type: EXPERIMENTAL
Intervention: Social-cognitive intervention to promote volunteering
Number of subjects: 360

Group type: COMPARATOR
Intervention: Active control intervention targeting physical activity
Number of subjects: 360
Study: 28698335

Group type: EXPERIMENTAL
Intervention: Standard antiepileptic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs
Number of subjects: 0
Study: 26467303

Group type: EXPERIMENTAL
Intervention: Common Elements Treatment Approach (CETA)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Wait-list Control (WLC) for CETA
Number of subjects: 378

Group type: COMPARATOR
Intervention: Wait-list Control (WLC) for CPT
Number of subjects: 378
Study: 23354911

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment (5 treatment sessions)
Number of subjects: 20
Study: 22093930

Group type: EXPERIMENTAL
Intervention: Knee arthroscopic synovectomy plus DMARD
Number of subjects: 97

Group type: COMPARATOR
Intervention: DMARD
Number of subjects: 97
Study: 19288305

Group type: EXPERIMENTAL
Intervention: Virtual Human Dissector (VHD) software
Number of subjects: 89

Group type: COMPARATOR
Intervention: Prosections and models in the dissecting room (DR)
Number of subjects: 89
Study: 16788707

Group type: EXPERIMENTAL
Intervention: Magnesium (300 mg/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 12182509

Group type: EXPERIMENTAL
Intervention: Patient education about the nature, causes, prevalence and treatment of depression
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care (no educational intervention)
Number of subjects: 70
Study: 10333193

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme supplementation (9 sachets per day containing lipase 36,000, amylase 27,000, protease 2400 FIP) for 14 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (identical-looking sachets) for 14 days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme supplementation
Number of subjects: 52
Study: 8542859

Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Control) 3 mL
Number of subjects: 60
Study: 2013674

Group type: EXPERIMENTAL
Intervention: 4 mol/L fraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mol/L fraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distilled water fraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other fractions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H2O fraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mol/L and H2O fractions
Number of subjects: 0
Study: 7032226

Group type: EXPERIMENTAL
Intervention: Single bedtime dose of chlorpromazine (300 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Divided doses of chlorpromazine (100 mg, thrice daily)
Number of subjects: 80
Study: 31508608

Group type: EXPERIMENTAL
Intervention: Instrumentation with master apical files (MAF) 50/0.05
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Instrumentation with master apical files (MAF) 55/0.05
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Instrumentation with master apical files (MAF) 60/0.05
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Instrumentation with master apical files (MAF) 40/0.15
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Instrumentation with master apical files (MAF) 45/0.15
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (uninstrumented roots)
Number of subjects: 100
Study: 28371811

Group type: EXPERIMENTAL
Intervention: Structured Brief Intervention (BI) lasting 15-30 min plus general health education, n = 118
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group receiving only general health education, n = 121
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Structured Brief Intervention (BI)
Number of subjects: 239
Study: 25673976

Group type: EXPERIMENTAL
Intervention: Dietary argan oil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cosmetic argan oil application
Number of subjects: 60

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 60
Study: 23958332

Group type: EXPERIMENTAL
Intervention: Brief Social Behavior and Network Therapy (B‐SBNT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Personal Goal Setting (PGS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: B‐SBNT and PGS (plus routine treatment)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Family members of patients
Number of subjects: 120
Study: 21199584

Group type: EXPERIMENTAL
Intervention: Opt-in consent
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Opt-out consent
Number of subjects: 1129
Study: 18289903

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GH) starting dose of 0.1mg/day, adjusted to maintain IGF‐I levels between 0 and 2 SDS for gender and age.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no GH therapy)
Number of subjects: 71
Study: 17294991

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSEA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Epidural analgesia (EA)
Number of subjects: 50
Study: 14693710

Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance (NGT) subjects (nonconverters)
Number of subjects: 2279

Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT) subjects who converted to diabetes
Number of subjects: 2279

Group type: COMPARATOR
Intervention: Impaired glucose tolerance subjects who converted to diabetes
Number of subjects: 2279

Group type: EXPERIMENTAL
Intervention: Converters (both NGT and impaired glucose tolerance)
Number of subjects: 2279

Group type: EXPERIMENTAL
Intervention: Changes in 2-h postglucose insulin levels
Number of subjects: 2279
Study: 10079412

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization (FISH) using chromosome probes 13, 16, 18, 21, 22, X, and Y
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: FISH using selected chromosome probes
Number of subjects: 33
Study: 7739943

Group type: EXPERIMENTAL
Intervention: Isoflurane (nitrous oxide, isoflurane 0.5‐1.0%)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Balanced anesthesia (nitrous oxide, fentanyl, midazolam)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups (Isoflurane and Balanced anesthesia)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 22
Study: 2390518

Group type: EXPERIMENTAL
Intervention: Oral fluorescein (25 mg/kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral fluorescein (capsules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous fluorescein
Number of subjects: 0
Study: 6947987

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate mouthrinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.035% alexidine mouthrinse
Number of subjects: 0
Study: 31122893

Group type: EXPERIMENTAL
Intervention: PRM-151
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: PRM-151 (crossover from placebo)
Number of subjects: 111
Study: 28703608

Group type: EXPERIMENTAL
Intervention: Systematic patient feedback using the Partners for Change Outcome Management System (PCOMS)
Number of subjects: 2247
Study: 26643821

Group type: EXPERIMENTAL
Intervention: Apical lead positioning
Number of subjects: 98

Group type: COMPARATOR
Intervention: Midseptal lead positioning
Number of subjects: 98
Study: 24587764

Group type: EXPERIMENTAL
Intervention: Suprapubic aspiration (SPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transurethral catheterization (TUC)
Number of subjects: 0
Study: 22233415

Group type: EXPERIMENTAL
Intervention: Thymosin alpha-1 1.6 mg SC twice weekly for 48 weeks
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Thymosin alpha-1 with standard of care
Number of subjects: 552

Group type: COMPARATOR
Intervention: Standard of care (peginterferon alfa-2a 180 mg/week with RBV 800-1200 mg/daily)
Number of subjects: 552
Study: 20123365

Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Multislice computed tomography (MSCT)
Number of subjects: 28
Study: 17570054

Group type: EXPERIMENTAL
Intervention: Habit reversal program with a pager to check tooth position and masticatory muscle tension, paging approximately once every 2 hours during the day for 4 weeks.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Behaviorally-modified dental intervention (splint therapy) using an interocclusal appliance worn up to 20 hours per day for 4 weeks.
Number of subjects: 8
Study: 16262733

Group type: EXPERIMENTAL
Intervention: Daily self-administered 6-month regimen of rifampicin and isoniazid
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Twice-weekly, directly observed 6-month regimen of rifampicin and isoniazid plus pyrazinamide for the first 2 months
Number of subjects: 268
Study: 12006901

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 123
Study: 10440436

Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (150 to 300 mg/kg/day in divided doses every 6 hours)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cefuroxime (50 to 100 mg/kg/day in divided doses every 6 or 8 hours)
Number of subjects: 98
Study: 7758054

Group type: EXPERIMENTAL
Intervention: NIF CC 30 mg daily with food
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: NIF GITS 30 mg daily with food
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: NIF CC 60 mg daily
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: NIF GITS 60 mg daily
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: NIF CC
Number of subjects: 228

Group type: COMPARATOR
Intervention: NIF GITS
Number of subjects: 228
Study: 31464592

Group type: EXPERIMENTAL
Intervention: Girls Active programme (intervention)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Training and resources of Girls Active programme (intervention)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Factors affecting implementation (intervention)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Feedback forms and attendance records (intervention)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Exit survey (intervention)
Number of subjects: 10

Group type: COMPARATOR
Intervention: School environment questionnaire (intervention and control)
Number of subjects: 10
Study: 28905108

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, days 1-21)
Number of subjects: 37

Group type: COMPARATOR
Intervention: S-1 (80-120 mg/day, days 1-14)
Number of subjects: 37
Study: 26738328

Group type: EXPERIMENTAL
Intervention: Combination therapy (Tamsulosin at 0.2 mg qd plus Xipayimaizipizi at 0.5 g tid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Tamsulosin at 0.2 mg qd)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 23427848

Group type: EXPERIMENTAL
Intervention: Affiliation arousal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social exclusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 21224838

Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 30 mg
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 18950736

Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate (150 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 17299073

Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 15203552

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg every other day orally
Number of subjects: 27
Study: 11593074

Group type: EXPERIMENTAL
Intervention: Fluvoxamine, Clomipramine, Citalopram, Paroxetine (standardized treatment over 12 weeks)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Not applicable (non-responders)
Number of subjects: 159
Study: 9390612

Group type: EXPERIMENTAL
Intervention: UpsherScope (Group US)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (Group DL)
Number of subjects: 300
Study: 7947206

Group type: EXPERIMENTAL
Intervention: Desonide (Locapred)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Excipient
Number of subjects: 40
Study: 3630963

Group type: COMPARATOR
Intervention: Normal-weight bulimic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anorectic-restrictor and anorectic-bulimic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight regain
Number of subjects: 0
Study: 29030140

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 5699

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 5699
Study: 27612583

Group type: EXPERIMENTAL
Intervention: HD13 trial (early-stage favourable)
Number of subjects: 4215

Group type: EXPERIMENTAL
Intervention: HD14 trial (early-stage unfavourable)
Number of subjects: 4215

Group type: EXPERIMENTAL
Intervention: HD15 trial (advanced-stage)
Number of subjects: 4215
Study: 25671925

Group type: EXPERIMENTAL
Intervention: Intravenous Morphine 0.1mg/kg and Intravenous lidocaine 1.5 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous Morphine 0.1mg/kg and lidocaine spray 1.5 mg/kg
Number of subjects: 60
Study: 24231018

Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP: 32% protein; 12.2 mg/day iron; 11.7 mg/day zinc)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP) with >=10% weight loss
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lower-protein diet (LP: 20%; 9.9 mg/day iron; 7.6 mg/day zinc) with >=10% weight loss
Number of subjects: 36
Study: 20121898

Group type: EXPERIMENTAL
Intervention: L-arginine (3 g three times daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (3 g three times daily)
Number of subjects: 30
Study: 19216279

Group type: EXPERIMENTAL
Intervention: Implant-supported removable partial denture (ISRPD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Conventional removable partial denture (CRPD)
Number of subjects: 5
Study: 15983759

Group type: EXPERIMENTAL
Intervention: Colistin
Number of subjects: 185

Group type: COMPARATOR
Intervention: Noncolistin
Number of subjects: 185
Study: 12668989

Group type: EXPERIMENTAL
Intervention: Amino acid solution (75 g)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10376778

Group type: EXPERIMENTAL
Intervention: Pistachio nuts (20% of daily caloric intake)
Number of subjects: 10
Study: 8911573

Group type: EXPERIMENTAL
Intervention: AIDS education and risk reduction training
Number of subjects: 27

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 27
Study: 2068695

Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microgram/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6370438

Group type: EXPERIMENTAL
Intervention: 0.05% diflorasone diacetate ointment in a vehicle of propylene glycol (PG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.05% fluocinonide ointment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate ointment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vehicle for diflorasone diacetate PG
Number of subjects: 24
Study: 30987643

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (measured by Blood Alcohol Concentration - BAC)
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Self-reported risky alcohol habits
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Support for restrictive alcohol policies
Number of subjects: 1410

Group type: EXPERIMENTAL
Intervention: Gender differences in BAC and drinking habits
Number of subjects: 1410
Study: 29929610

Group type: EXPERIMENTAL
Intervention: Double volume saline (2 ml/kg/h for 12 h before and after the procedure)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Standard volume saline (1 ml/kg/h for 12 h before and after the procedure)
Number of subjects: 303
Study: 27472964

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 60
Study: 24528614

Group type: EXPERIMENTAL
Intervention: Oral rapamycin plus bare-metal stent (OR)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Drug-eluting stent (DES)
Number of subjects: 200
Study: 22950365

Group type: EXPERIMENTAL
Intervention: Traditional authorship (n = 35)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Ghostwritten paper (n = 32)
Number of subjects: 67
Study: 20232758

Group type: EXPERIMENTAL
Intervention: Oral simvastatin (40 mg/d) plus topical betamethasone (50% in petrolatum) for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral placebo plus topical betamethasone (50% in petrolatum) for 8 weeks
Number of subjects: 30
Study: 17683108

Group type: EXPERIMENTAL
Intervention: Sober condition
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Intoxicated condition
Number of subjects: 1232
Study: 15050090

Group type: EXPERIMENTAL
Intervention: Family cognitive‐behavioral therapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Individual cognitive‐behavioral therapy
Number of subjects: 182
Study: 11150449

Group type: EXPERIMENTAL
Intervention: Routine admission after isolated mild closed head injury
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 1033
Study: 9734756

Group type: EXPERIMENTAL
Intervention: Zinc supplementation 1.5 mg/kg for 15 days
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Zinc supplementation 6.0 mg/kg for 15 days
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Zinc supplementation 6.0 mg/kg for 30 days
Number of subjects: 141
Study: 7520659

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) treatment
Number of subjects: 0
Study: 2648105

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 45

Group type: COMPARATOR
Intervention: Suprofen
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 4919024

Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice a day
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study: 31623324

Group type: EXPERIMENTAL
Intervention: Photo story booklet regarding doctor‐patient communication
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non‐narrative brochure
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Photo story booklet (from interview study)
Number of subjects: 120
Study: 28403850

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 25218264

Group type: EXPERIMENTAL
Intervention: Pressurised irrigation
Number of subjects: 256
Study: 25234525

Group type: EXPERIMENTAL
Intervention: Papilla base incision (PBI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intrasulcular flap (IS)
Number of subjects: 24
Study: 22354598

Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg three times daily
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg three times daily
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg three times daily
Number of subjects: 277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study: 19124036

Group type: EXPERIMENTAL
Intervention: Dichoptic masking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual differences in dichoptic masking and binocular rivalry measures
Number of subjects: 0
Study: 17509689

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib sodium (1 mg or 3 mg) every 6 weeks for 54 weeks
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 147
Study: 15632883

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coumadin plus aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cilostazol plus aspirin
Number of subjects: 0
Study: 11447356

Group type: EXPERIMENTAL
Intervention: Plyometric training (drop jumps from 50 cm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plyometric training (drop jumps from 100 cm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (regular midseason training)
Number of subjects: 0
Study: 9820393

Group type: EXPERIMENTAL
Intervention: Self-reported rectal bleeding
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Self-reported rectal bleeding (blood on wiping)
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Self-reported rectal bleeding (blood coating stools)
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Self-reported rectal bleeding (dark blood mixed in stools)
Number of subjects: 1643

Group type: COMPARATOR
Intervention: Age group comparison
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Constipation as a predictor
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Diarrhea as a predictor
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Health care seeking behavior
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: History of abdominal surgery as a predictor
Number of subjects: 1643
Study: 8575676

Group type: EXPERIMENTAL
Intervention: Gyno-Pevaryl 150 treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (without G-P 150 treatment)
Number of subjects: 50
Study: 2234646

Group type: EXPERIMENTAL
Intervention: Low dose aspirin therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Public promotion of a healthy lifestyle
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Drug therapy or research in pregnancy
Number of subjects: 39
Study: 685753

Group type: EXPERIMENTAL
Intervention: Aspirin, 1200 mg/day
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Aspirin + Sulfinpyrazone
Number of subjects: 585

Group type: COMPARATOR
Intervention: Sulfinpyrazone alone
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 585